Osimertinib

An analysis of global online conversations among health care professionals on social media in February showed an overarching sense of enthusiasm about FDA approval of the first cellular therapy to treat unresectable or metastatic melanoma.

The FDA approved osimertinib plus platinum-based chemotherapy for certain adults with locally advanced or metastatic non-small cell lung cancer.

MADRID — Healio spoke with Hossein Borghaei, DO, MS, about the results of the MARIPOSA-2 trial, which were presented at ESMO Congress.

MADRID — In this video interview with Healio, Hossein Borghaei, DO, MS, talked about results from the MARIPOSA study presented at ESMO Congress.

MADRID — A novel antibody-drug conjugate plus osimertinib showed clinical activity and a manageable safety profile in patients with relapsed/refractory, EGFR-mutated non-small cell lung cancer, according to a presentation at ESMO Congress.

MADRID — Amivantamab plus chemotherapy improved PFS, objective response rate and intracranial PFS compared with chemotherapy alone in patients with EGFR-mutated advanced non-small cell lung cancer after progression on osimertinib.

MADRID — In this video, Julia Rotow, MD, clinical director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, discussed MARIPOSA data on amivantamab in EGFR-mutated advanced lung cancer presented at ESMO Congress.

MADRID — The combination of amivantamab and lazertinib improved PFS compared with osimertinib as first-line treatment for EGFR-mutated advanced non-small cell lung cancer, according to study results presented at ESMO Congress.

Healio spoke with Melina Elpi Marmarelis, MD, about data from the INSIGHT 2 trial presented at this year’s International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Melina Elpi Marmarelis, MD, discussed research on the use of osimertinib versus durvalumab following chemoradiation in patients with stage III EGFR-mutated NSCLC.